Core Laboratories (NYSE: CLB ) is expected to report Q4 earnings on Jan. 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Core Laboratories's revenues will grow 1.0% and EPS will grow 3.7%.
The average estimate for revenue is $246.3 million. On the bottom line, the average EPS estimate is $1.13.
Last quarter, Core Laboratories reported revenue of $245.4 million. GAAP reported sales were 6.1% higher than the prior-year quarter's $231.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.13. GAAP EPS of $1.14 for Q3 were 23% higher than the prior-year quarter's $0.93 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 36.7%, 170 basis points better than the prior-year quarter. Operating margin was 30.0%, 200 basis points better than the prior-year quarter. Net margin was 22.2%, 280 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $973.0 million. The average EPS estimate is $4.48.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 576 members out of 587 rating the stock outperform, and 11 members rating it underperform. Among 145 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 144 give Core Laboratories a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Core Laboratories is hold, with an average price target of $127.71.
Is Core Laboratories the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
- Add Core Laboratories to My Watchlist.